Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...
After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...
“Emphysema is part of a group of lung conditions which comes under the umbrella term chronic obstructive pulmonary disease ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...
Study finds home high-flow therapy may enhance COPD recovery after severe exacerbations, improving symptoms and reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback